Unique Catalog of Over 300 Aptamers Provides Alternative to Antibodies
Aptagen, (www.aptagen.com), creators of the industry’s first catalog of aptamers, DNA/RNA oligonucleotides, and peptides has updated their library of products to include over 300 custom-order aptamer sequences. This rapidly growing network of sequences can be used in applications including drug discovery, therapeutics, and diagnostic and biomarker tools. Due to their reduced cost, faster production times, and batch-to-batch consistency, aptamers are quickly becoming a viable alternative to traditional antibodies. The benefits continue post-synthesis too, as aptamers exhibit higher binding affinity and specificity than antibodies. Aptagen’s library of sequences can be used for targeting small organics, peptides, proteins, viruses, cells and bacteria.
Aptagen’s President and CEO, Tom Caltagirone, explains, “There are many sources for commercially-available antibodies, but until we developed it, there was no aptamer catalog equivalent. Aptagen has committed to making it easy for researchers and production facilities to source and order high-quality aptamers as a faster and better alternative to antibodies”. The catalog is constantly being updated to highlight the latest aptamer discoveries. To help users easily maneuver through the growing list of available products, Aptagen has streamlined its online ordering platform.
To view the aptamer catalog online, request a hard-copy, submit a project inquiry, or order a custom oligo, visit www.aptagen.com or contact us at [email protected]
About Aptagen LLC.
Aptagen, LLC is a biotechnology company offering aptamer products as research reagents, diagnostic and biomarker discovery tools, as well as for use in drug discovery and targeted delivery for therapeutics and bioindustrial applications. Located in Jacobus PA, Aptagen has 20 years of experience in developing aptamers for all types of downstream applications.
Contact:
G. Thomas Caltagirone, Ph.D.
President & CEO
Aptagen LLC
717-278-2436
